Korean Circ J.
2006 Dec;36(12):794-801. 10.4070/kcj.2006.36.12.794.
The Efficacy and Safety of an Immunosuppressive Regimen Including the Use of Mycophenolate Mofetil and an Interleukin-2 Monoclonal Antibody in Heart Transplant Patients
- Affiliations
-
- 1Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. jjkim@amc.seoul.kr
- 2Department of Thoracic Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- 3Organ Transplant Program, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- KMID: 2013160
- DOI: http://doi.org/10.4070/kcj.2006.36.12.794
Abstract
-
BACKGROUND AND OBJECTIVES: An immunosuppressive regimen including the use of mycophenolate mofetil (MMF) and an interleukin-2 monoclonal antibody (IL2mAb) has shown promise to prevent acute rejection after heart transplantation. There has been a lack of report on the evaluation of the efficacy and safety of this regimen in patients receiving heart transplants in Korea.
SUBJECTS AND METHODS
From November 1992 to December 2003, 111 consecutive patients who had received heart transplants in our institute were classified into two groups: patients who received the immunosuppressive regimen with MMF and an IL2mAb (group A, n=51) and patients who did not receive the regimen (group B, n=60). We compared the clinical outcomes of patients in each group including the survival rate and the occurrence of acute rejection and infection at 24 months post transplantation.
RESULTS
Both drugs were tolearated in all patients except in 5 patients who complained of gastrointestinal side effects due to MMF. Despite a longer ischemic time (137.4+/-54.6 vs. 92.3+/-25.8 hours, p<0.05) and a lower serum level of cyclosporine (212.3+/-66.8 vs. 259.1+/-62.1 ng/mL, p<0.05), the rate of treatment for acute rejection was lower in group A than in group B (16% vs. 53%, p<0.05). In addition, the median time to the first treatment for acute rejection was almost twice as long for group A as for group B (91 vs. 43 days, p<0.05). The 2-year survival rate and the incidence of major infection requiring hospitalization in both groups were 94% vs. 88% and 26% vs. 21%, respectively, which were not statistically different.
CONCLUSION
An immunosuppressive regimen including the use of MMF and an IL2mAb is efficacious and safe as a prophylaxis against acute rejection without the increased risk of major infection in patients who have received heart transplants in Korea.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Efficacy and Outcome of Reduced Dose of Tacrolimus in Renal Transplantation
- The Effectiveness of Mycophenolate Mofetil(MMF) in the Prevention of Acute Rejection and Graft Outcome in Clinical Renal Transplantation
- 'Rescue Therapy' with Mycophenolate Mofetil in Non-transplant Renal Disease Patients Experienced Conventional Immunosuppressive Treatments : Clinical Observation
- Case of ABO-Incompatible Living Donor Kidney Transplantation without Blood Products in a Jehovah's Witness
- Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
